Clinical Trial Update: Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects [Phase 1]

View source ↗

Summary

A completed Phase 1 study assessing safety, tolerability and pharmacokinetics of KPG-818 in patients with hematological malignancies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematological Malignancies

Drugs mentioned

• KPG-818

Snippet

Sponsor: Kangpu Biopharmaceuticals, Ltd. | Conditions: Hematological Malignancies | Phase 1 | Status: COMPLETED